• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Novartis

NYSE:NVS

$51.96 $0.23 (0.44%)

REAL-TIME: Last trade at

Jump to this page for:

Related Resources

Novartis India To Pay 200% Dividend For FY12

5/24/2012 by RTTNews

Why Buying 'Market Outperform' Zalicus At A Discount Is Savvy

5/24/2012 by Seeking Alpha

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

5/23/2012 by PR Newswire

Alcon Research Ltd. a Novartis company

5/23/2012 by Pharmalicensing.com - UK

Novartis Progresses with NVA237 - Analyst Blog

5/21/2012 by Zacks Investment Research

Novartis Progresses with NVA237

5/21/2012 by Zacks Equity Research Analyst Blog

Sachs Associates to host a forum

5/21/2012 by Theflyonthewall.com

Novartis Sees Positive Phase III Data for COPD Candidate

5/18/2012 by Drug Topics

Perrigo announces FDA final approval of OTC Lanosoprazole 15mg capsules

5/18/2012 by Theflyonthewall.com

NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update

5/17/2012 by Tobacco.org

Novartis NVA237 Phase III data showed rapid, sustained improvement

5/17/2012 by Theflyonthewall.com

NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update

5/17/2012 by PR Newswire

Eli Lilly Could Sink On Drug Collusion In India

5/16/2012 by Seeking Alpha

Positive Data on Novartis' Lucentis - Analyst Blog

5/15/2012 by NASDAQ

Positive Data on Novartis' Lucentis - Analyst Blog

5/15/2012 by Zacks Investment Research

Positive Data on Novartis' Lucentis

5/15/2012 by Zacks Equity Research Analyst Blog

Pernod Ricard, Kodak, Apple, Novartis: Intellectual Property

5/15/2012 by Bloomberg.com

Novartis Sues Lupin, Torrent Over Blood-Pressure Medicine

5/14/2012 by Bloomberg.com

Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novartis - Press Releases

5/14/2012 by Zacks Investment Research

Insider training

5/13/2012 by FT.com

Finding Stability Amid Europe Woes

5/13/2012 by Morningstar

Novartis to investigate alleged approval irregularities in India, Reuters says

5/10/2012 by Theflyonthewall.com

Novartis (NVS) Updates on Lucentis; Shows Encouraging Results in DME Patients

5/10/2012 by StreetInsider.com

Novartis initiated with a Buy at Societe Generale

5/10/2012 by Theflyonthewall.com

Novartis Scores in Phase III Study - Analyst Blog

5/9/2012 by Zacks Investment Research

Novartis Scores in Phase III Study

5/9/2012 by Zacks Equity Research Analyst Blog

6 Flatlining Healthcare Stocks to Sell

5/9/2012 by InvestorPlace

Lucentis Vs Avastin: Equally Effective For Wet AMD; Can Cost Differentiate?

5/9/2012 by RTTNews

Novartis: A Sleeper Or A Headache?

5/9/2012 by Seeking Alpha

Perrigo's CEO Discusses Q3 2012 Results - Earnings Call Transcript

5/8/2012 by Seeking Alpha

Novartis: A Deeply Undervalued Buy At $54

5/7/2012 by Seeking Alpha

Novartis hurt by competition from generics

4/24/2012 by San Francisco Chronicle - San Francisco CA

Drugs giant in legal fight to stop NHS switching to cheap rival for its eye disease treatment

4/24/2012 by Daily Mail - London - UK

Novartis halts trial on Hepatitis C drug

4/20/2012 by Triangle Business Journal - Raleigh NC

Novartis breaks ground on Maya Lin-designed campus

4/12/2012 by Boston Herald - Boston MA